Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: marine anti-plaque compounds - Aphios

Drug Profile

Research programme: marine anti-plaque compounds - Aphios

Alternative Names: Asterias; Marine anti-plaque compounds - Aphios

Latest Information Update: 28 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aphios Corporation
  • Developer Aphios Corporation; Massachusetts Institute of Technology; Scripps Institution of Oceanography
  • Class Anti-inflammatories; Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gingivitis

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for preclinical development in Gingivitis in USA (PO, Paste)
  • 07 Apr 2021 Preclinical development is still ongoing for Gingivitis in USA (Aphios Corporation website, April 2021)
  • 07 Apr 2021 Aphios Corporation receives SBIR grant from National Institute of Dentistry and Craniofacial Research (NIDCR), National Institutes of Health for Asterias before April 2021 (Aphios Corporation website, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top